|
|
|
|
Myelodysplastic Syndromes
CORRECTING and REPLACING NCCN Announces Important Updates to ... Mar 2, 2006
Genetic Engineering News, ...revisions. The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Myelodysplastic Syndromes (MDS) Guidelines. ...
NCCN Announces Important Updates to Myelodysplastic Syndromes ... Mar 2, 2006
PharmaLive.com (press release), Pa.--(BUSINESS WIRE)--Mar 2, 2006 - The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Myelodysplastic Syndromes (MDS) Guidelines. ...
NCCN Announces Important Updates to Myelodysplastic Syndromes ... Mar 3, 2006
DG News JENKINTOWN, PA -- March 3, 2006 -- The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Myelodysplastic Syndromes (MDS) Guidelines. ...
Millennium CEO says may form strategic partnership Mar 10, 2006
Reuters The challenge for Millennium in 2006 is the likely erosion of Velcade sales by Revlimid, a drug recently approved to treat myelodysplastic syndromes, a group ...
FDA Grants Priority Review for REVLIMID(R) sNDA for Treatment of ... Mar 3, 2006
International News Service, ...approved by the FDA for treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated ...
Priority multiple myeloma review for Celgene drug Mar 7, 2006
Pharmaceutical Business Review ...is approved by the FDA for treatment of patients with transfusion-dependent anemia due to low or intermediate-1-risk myelodysplastic syndromes (MDS) associated ...
Books and Media Received Mar 7, 2006
Journal of American Medical Association (subscription), Myelodysplastic Syndromes by H. Joachim Deeg, David T. Bowen, Steven D. Gore, Torsten Haferlach, Michelle M. Le Beau, and Charlotte Niemeyer (Hematologic ...
Topotecan/Cytarabine Regimen May Be Effective Alternative for MDS Feb 22, 2006
Cancer Consultants (press release), ...the chemotherapy combination consisting of topotecan (Hycamtin®) and cytarabine (Ara-C®) appears to be effective in the treatment of myelodysplastic syndromes ...
Couple creates Web site for families facing aplastic anemia Feb 26, 2006
Beckley Register-Herald (subscription), Aplastic anemia and myelodysplastic syndromes are non-contagious, and often fatal, blood diseases that occur when the bone marrow stops making enough healthy ...
Celgene Selects McKesson Specialty as a RevAssist Program Pharmacy ... Feb 13, 2006
PR Newswire (press release), ...oral medication for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated ...
Drug, biotech stocks slip into negative territory Mar 3, 2006
Investor's Business Daily (subscription) The drug is already approved to treat anemia associated with certain myelodysplastic syndromes. Meanwhile, NitroMed (NTMD) sank 8% to $8.72. ...
PHARMION CORPORATION ANNOUNCES 2005 FINANCIAL Feb 22, 2006
ITNews, ...in hematological malignancies and solid tumors, as well as a Phase I/II study in acute myelogenous leukemia and high-risk Myelodysplastic syndromes (MDS) in ...
Fund manager searches for bright biotech stars Feb 15, 2006
Investor's Business Daily (subscription) Similarly, he added, Celgene's Revlimid, currently approved for certain types of myelodysplastic syndromes, could get approval later this year for treatment of ...
Bone marow disease at core Feb 16, 2006
Cape Gazette, Donations to the Aplastic Anemia and MDS (myelodysplastic syndromes) International Foundation Inc., can be made through the website.
SuperGen Reports 2005 Fourth Quarter and Year-End Financial ... Feb 23, 2006
PR Newswire (press release), Updated results from an alternative dosing study of Dacogen in patients with myelodysplastic syndromes (MDS) and initial data from a phase 2 trial of Dacogen ...
Revlimid® Approved for Myelodysplastic Syndromes Dec 28, 2005
Cancer Consultants (press release), The US Food and Drug Administration (FDA) has approved Revlimid® (lenalidomide) for the treatment of patients with myelodysplastic syndromes (MDS). ...
New Drug for Some Myelodysplastic Syndromes Dec 29, 2005
ACS News Center, The US Food and Drug Administration has approved the drug Revlimid (lenalidomide) for people with a certain type of myelodysplastic syndrome, a bone marrow ...
Analysts' Stock Picks: Part 1 Jan 23, 2006
BusinessWeek Revlamid, a next-generation drug that recently won approval for treating patients with the cancer-related blood disorders known as myelodysplastic syndromes. ...
SIXTH ANNUAL REPORT: FUTURE BLOCKBUSTERS Dec 30, 2005
Med Ad News (subscription), ...defects. Celgene is developing Revlimid to treat fatal blood disorders known as myelodysplastic syndromes, as well as cancer. Revlimid ...
FDA Grants REVLIMID(R) NDA Approval Dec 27, 2005
Yahoo! News (press release) ...is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with ...
Highlights of Economic and Business Growth in the Tampa Bay Region ... Jan 10, 2006
PR Newswire (press release), Revlimid is designed to treat patients with transfusion-dependent anemia due to low or intermediate risk myelodysplastic syndromes (MDS) associated with a ...
Celgene shares rise after FDA approves drug Dec 28, 2005
Reuters ...after US regulators approved its drug Revlimid to treat certain patients with anemia caused by a group of blood disorders known as myelodysplastic syndromes. ...
UPDATE 1-Celgene shares up as FDA approves blood drug Dec 28, 2005
Reuters ...percent on Wednesday after US regulators approved its drug Revlimid to treat certain patients with a group of blood disorders known as myelodysplastic syndromes ...
Celgene Corporation Reviews Recent Highlights and Outlines 2006 ... Jan 9, 2006
MSN Money ...drug REVLIMID for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated ...
Thalomid gives hope for blood cancer sufferers Jan 9, 2006
News-Medical.net, Thalomid and a successor drug, Revlimid, which was approved by the FDA in December for treating a group of blood disorders known as myelodysplastic syndromes. ...
Celgene wins OK for blood cancer drug Dec 29, 2005
NorthJersey.com, ...dollar product. The drug has been approved for treating myelodysplastic syndromes, a form of cancer that causes anemia. Celgene ...
MGI PHARMA Provides Corporate Update; 2005 Aloxi(R) Injection ... Jan 10, 2006
Genetic Engineering News, ...leukemia (AML) and a phase 2 trial designed to evaluate an alternate dosing regimen of Dacogen injection in patients with myelodysplastic syndromes (MDS) were ...
Meghan Fitzgerald Joins Vion's Senior Management Team Jan 10, 2006
PR Newswire (press release), Trials of Cloretazine(R) as a single agent in previously untreated elderly acute myelogenous leukemia and high-risk myelodysplastic syndromes, adult and ...
Telik expects simultaneous cancer trial results Jan 10, 2006
Reuters Also this year, Wick said Telik plans to launch a Phase 3 trial of Telintra, which is being developed to treat myelodysplastic syndromes and other blood ...
FDA Approvals: Orencia and Revlimid Dec 29, 2005
Medscape (subscription) ...and lenalidomide capsules for the treatment of transfusion-dependant anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with ...
Methodist minister Vaughan, 92, kept on joking 'till the end' Jan 9, 2006
San Antonio Express (subscription), ...to God and country led to a 22-year career as a Navy chaplain that took him to the Pacific Theater and Korea, died at home Saturday of myelodysplastic syndromes ...
FDA approves REVLIMID for MDS Dec 29, 2005
Cancerfacts.com, ..."The FDA approval of REVLIMID offers a new therapeutic option to this particular group of patients with myelodysplastic syndromes," said Dr. Graham Burton ...
New Drug Offers Hope To MDS Patients Jan 4, 2006
Pittsburgh Channel.com, ...doctors say it offers new hope and a clinical benefit to some patients who depend on blood transfusions because of a disorder called myelodysplastic syndromes. ...
US Stocks Recover on Confidence Data; Energy Shares Gain Listen Dec 28, 2005
Bloomberg Sales of Revlimid, used to treat anemia related to a fatal blood cancer, myelodysplastic syndromes, may reach $700 million by 2008, according to estimates by ...
Celgene: FDA Approves Anemia Drug Dec 28, 2005
MSN Money The treatment is for blood transfusion-dependent patients with low- and intermediate-risk of myelodysplastic syndromes -- a group of disorders in which blood ...
Moffitt doctor leads study for drug to treat blood disorder Dec 29, 2005
Tampa Bay Business Journal, FDA approval offers a new therapeutic option to a particular group of patients with myelodysplastic syndromes, Dr. Graham Burton, senior vice president ...
FDA OKs Drug for Rare Bone Marrow Disorder Dec 28, 2005
ABC News ...defects has won FDA approval to treat anemia in people who suffer from certain kinds of rare bone marrow disorders known as myelodysplastic syndromes, or MDS. ...
Approval of Cancer Drug Lifts Celgene Stock Dec 28, 2005
New York Times, ...pill. The Food and Drug Administration cleared Revlimid for myelodysplastic syndromes, which cause anemia and infections. Revlimid ...
FDA approves new drug for rare blood disorder Dec 29, 2005
Xinhua, Corp announced Tuesday that the Food and Drug Administration has approved Revlimid, a new drug for the treatment of patients with myelodysplastic syndromes (MDS ...
Celgene Could See 'Cascade Of Positive Events' Dec 28, 2005
Forbes ...news that the Food and Drug Administration approved Celgene (nasdaq: CELG - news - people )'s Revlimid for the treatment of myelodysplastic syndromes, a group ...
Celgene Wins FDA Approval For Revlimid Dec 28, 2005
Business Online, US Food and Drug Administration had approved Revlimid to treat severe anemia associated with a group of blood disorders called myelodysplastic syndromes, or MDS ...
FDA OK's Celegene's Revlimid Dec 28, 2005
United Press International ...has OK'd the drug for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) linked to ...
FDA approves Celgene cancer drug Dec 28, 2005
Newark Star Ledger, ...blood cancer. The new-generation drug will be prescribed for myelodysplastic syndromes, or MDS, a group of blood cancers. Up to ...
Business briefs, December 29 Dec 28, 2005
Rocky Mountain News, ...pill. The Food and Drug Administration cleared Revlimid for myelodysplastic syndromes, or MDS, which cause anemia and infections. ...
Anti-Blood Disease Drug A Breakthrough Jan 6, 2006
WNBC, Revlimid offers new hope and clinical benefits to patients with myelodysplastic syndromes, or MDS, a group of bone marrow disorders that causes anemia ...
FDA approves Revlimid for rare blood disorder Dec 29, 2005
myDNA.com, The Food and Drug Administration (FDA) has granted approval of Revlimid (lenalidomide) for the treatment of myelodysplastic syndromes (MDS). ...
Street Chatter: Target, DaimlerChrysler, and Celgene Dec 28, 2005
Schaeffers Research, ...and Drug Administration (FDA) approved its Revlimid drug to treat severe anemia associated with a group of blood disorders called myelodysplastic syndromes (MDS ...
Celgene "neutral weight" Dec 28, 2005
New Ratings ...that the company announced that it has won the US FDA approval for its Revlimid drug for the treatment of low-or intermediate-1-risk myelodysplastic syndromes. ...
New Clinical Data Shows Innovative Treatment Removes Iron from ... Jan 8, 2006
Al-Bawaba, ...treat certain types of rare chronic blood disorders, including thalassemia and sickle cell disease, as well as other rare anemia and myelodysplastic syndromes. ...
A Cancer Treatment in the Spice Cabinet? Jan 3, 2006
ACS News Center, Studies from other institutions, both in the US and overseas, are looking at curcumin as a potential treatment for myelodysplastic syndromes, and for ...
S&P Downgrades TiVo to Sell Dec 28, 2005
BusinessWeek The FDA okays Revlimid to treat patients with transfusion-dependent anemia from low- or intermediate-1-risk myelodysplastic syndromes associated with deletion ...
Revlimid approval brings year-end cheer to Celgene Jan 2, 2006
Pharma Times (subscription), ...after the US Food and Drug Administration approved its Revlimid product as a treatment for patients with anaemia caused by myelodysplastic syndromes, a group ...
FDA Approves Anemia-MDS Drug Dec 28, 2005
WFMY News 2, Washington, DC -- It can now be used for people who suffer from certain kinds of rare bone marrow disorders known as myelodysplastic syndromes, or MDS. ...
Revlimid® Plus Dexamethasone for Relapsed Multiple Myeloma ... 21 Dec 2005
Cancer Consultants (press release), ...myeloma effects. Revlimid has recently been submitted to the FDA for review of treatment of myelodysplastic syndromes (MDS). Revlimid ...
Azacitidine (Vidaza) for Myelodysplastic Syndromes (MDS) Does Not ... Dec 13, 2005
DG News ATLANTA, GA -- December 13, 2005 -- Azacitidine (Vidaza) treatment for myelodysplastic syndromes (MDS) does not increase the rate of infection or bleeding ...
Aranesp® Effective in Low and Intermediate Risk Myelodysplastic ... Dec 7, 2005
Cancer Consultants (press release), Myelodysplastic syndromes have evolved from a group of diseases for which no treatment options were available to one in which the supportive growth factors ...
Aranesp® Effective in Myelodysplastic Syndromes Dec 2, 2005
Cancer Consultants (press release), ...the Annals of Oncology, Aranesp (darbepoetin afla) is effective in the treatment of anemia in patients with low or intermediate-risk myelodysplastic syndromes. ...
Dacogen(TM) (Decitabine) Injection Data Presented at American ... Dec 12, 2005
Genetic Engineering News, Updated results from an alternative dosing study of Dacogen injection in patients with myelodysplastic syndromes (MDS) and initial data from a phase 2 trial of ...
Azacitidine (Vidaza) Is First Drug to Show Survival Benefit in ... Dec 12, 2005
DG News ATLANTA, GA -- December 12, 2005 -- A significantly higher percentage of elderly patients with high-risk myelodysplastic syndromes (MDS) who received treatment ...
Company news Dec 15, 2005
Minneapolis Star Tribune (subscription), ...said that the US Food and Drug Administration has accepted the companies' Nov. 15 resubmission of Dacogen injections for myelodysplastic syndromes. ...
REVLIMID(R) Clinical Results as Oral Treatment Regimen in ... Dec 13, 2005
PR Newswire (press release), ...by Celgene as a treatment for a broad range of hematology and oncology conditions, including; multiple myeloma, myelodysplastic syndromes (MDS), chronic ...
Source: Pharmion Corporation Dec 8, 2005
Yahoo! News (press release) Vidaza is the only approved therapy for myelodysplastic syndromes (MDS) and is indicated for the treatment of all five subtypes of the condition. ...
Dacogen(TM) (Decitabine) Injection Complete Response Accepted for ... Dec 15, 2005
Genetic Engineering News, ...resubmission as of November 15, 2005 as a complete response to the Approvable Letter for Dacogen(TM) (decitabine) injection for myelodysplastic syndromes (MDS ...
Blood drive set for sick children Dec 15, 2005
Pittsburgh Tribune-Review, Justess was diagnosed in May with a rare form of leukemia called Myelodysplastic Syndromes (MDS), a disorder where the bone marrow produces too few red blood ...
3M to buy Siemens flexible circuit line Dec 16, 2005
Pioneer Press, ...said that the US Food and Drug Administration has accepted the companies' resubmission for approval of their Dacogen injection for myelodysplastic syndromes. ...
Source: Quest Diagnostics Incorporated Dec 9, 2005
Yahoo! News (press release) Hypomethylation Therapy of Decitabine in Patients with Myelodysplastic Syndromes (MDS) Induces Apoptosis and Reduces Proliferation.
Celgene Seen As 'Key Portfolio Holding' In Biotech Dec 12, 2005
Forbes But all eyes are on Revlimid's New Drug Application for myelodysplastic syndromes, which refers to a group of blood disorders, expected by the FDA Jan. ...
Advanced multiple myeloma: Revlimid improves overall survival and ... Dec 12, 2005
Xagena.it, ...by Celgene as a treatment for a broad range of hematology and oncology conditions, including; multiple myeloma, myelodysplastic syndromes ( MDS ), chronic ...
Clinical Data on Vidaza (Azacitidine for Injectable Suspension) in ... Dec 12, 2005
PharmaLive.com (press release), Vidaza is currently the only marketed treatment for all five subtypes of myelodysplastic syndromes (MDS), including refractory anemia (RA), refractory anemia ...
Symposium to highlight developments in key diseases Nov 25, 2005
Gulf Daily News, ...feature parallel symposiums on current concepts in gynaecological pathology and current trends in the acute leukaemia as well as myelodysplastic syndromes (MDS ...
Bone marrow drive gives Marine hope Dec 2, 2005
Marines.com Myelodysplastic syndromes are difficult to treat because of the unusual combination of hyperactive marrow but inadequate blood-cell production. ...
Top Advances in Cancer Treatment for 2005 Chosen by Oncologists Dec 2, 2005
SeniorJournal.com, ...advances included vaccines for HPV, the virus closely associated with cervical cancer, and new treatments for stomach cancer, myelodysplastic syndromes, and an ...
Cancer Group Lists Top Treatment Advances for 2005 Dec 2, 2005
Forbes Bexxar combination therapy against B-cell lymphomas; Revlimid's success in treating killer bone marrow disorders called myelodysplastic syndromes (MDS); the ...
Bucks for the battle Nov 21, 2005
Herald & Review, McLeod has a rare bone marrow disorder called myelodysplastic syndromes. "It is a blood disorder that leads into leukemia," McLeod said she has been told. ...
Seattle Genetics targets leukemia Nov 18, 2005
Everett Navy Base News, The study will target patients with acute myeloid leukemia, a cancer of the blood and bone marrow, and related myelodysplastic syndromes who are not eligible ...
Bytes, November 21 Nov 21, 2005
Rocky Mountain News, ...of Boulder, an interactive and strategic marketing firm, launched a new Web site for the Aplastic Anemia and Myelodysplastic Syndromes International Foundation ...
Reduced-Intensity Allogeneic Stem Cell Transplants with ... Nov 10, 2005
Cancer Consultants (press release), Patients treated were diagnosed with non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia ...
Exjade®, a breakthrough once-daily oral iron chelator, receives ... Nov 6, 2005
Medical News Today (press release), ...treat certain types of rare chronic blood disorders, including thalassemia and sickle cell disease, as well as other rare anemias and myelodysplastic syndromes ...
Celgene Corporation Reports Strong Operating, Regulatory and ... Nov 3, 2005
PR Newswire (press release), Application (MAA) Accepted by the EMEA to Evaluate REVLIMID as Oral Targeted Therapy for Treatment of Patients with Myelodysplastic Syndromes (MDS) with ...
Exjade(R), a Breakthrough Once-Daily Oral Iron Chelator, Receives ... Nov 2, 2005
PR Newswire (press release), Approval makes iron chelation more accessible to patients suffering from diseases such as sickle cell, thalassemia and myelodysplastic syndromes EAST HANOVER ...
Celgene Corporation Reports Strong Operating, Regulatory and ... Nov 3, 2005
PR Newswire (press release), ...to advance US and European regulatory filings, Celgene increased R&D expenditures in REVLIMID(R) regulatory programs in myelodysplastic syndromes and multiple ...
REVLIMID(R) Marketing Authorization Application Accepted by EMEA ... Oct 26, 2005
PR Newswire (press release), REVLIMID Being Evaluated by the EMEA as Oral Targeted Therapy for Treatment of Patients with Myelodysplastic Syndromes (MDS) with Deletion 5q Chromosomal ...
Exjade Wins FDA Approval as Oral Iron Chelator Nov 2, 2005
MedPage Today, ...two and older whose iron overload resulted from frequent blood transfusions for thalassemia and sickle cell disease, rare anemias, and myelodysplastic syndromes ...
REVLIMID(R) Marketing Authorization Application Accepted by EMEA ... Oct 27, 2005
PR Newswire (press release), ...authorization to market REVLIMID as a treatment for transfusion-dependent anemia due to low- or intermediate-1- risk myelodysplastic syndromes (MDS) associated ...
Structure of the Hematological Cancer Market and Its Perspectives Nov 3, 2005
Business Wire (press release), ...intracellular pathways--under development at a multitude of small oncology companies for leukemias and myelodysplastic syndromes, lymphomas (Hodgkin's disease ...
Senate approves Neilson nomination to federal appeals court Oct 27, 2005
Detroit Free Press, Neilson underwent a bone marrow transplant two years ago for treatment of myelodysplastic syndromes, a group of disorders in which the marrow doesn't produce ...
Cholestech 2Q sales and profit jump Oct 26, 2005
San Jose Mercury News, The drug, Dacogen, is an injection for myelodysplastic syndromes, a condition in which bone marrow does not produce enough blood cells. ...
Pharmion Reports Third Quarter 2005 EPS of $0.27, Nine Month EPS ... Oct 25, 2005
PR Newswire (press release), Regulatory and Development Update Pharmion is currently sponsoring a study of 354 high-risk myelodysplastic syndromes (MDS) patients comparing Vidaza to best ...
MGI PHARMA and SuperGen Provide Regulatory Updates for Dacogen(TM) ... Oct 26, 2005
Genetic Engineering News, ...(Nasdaq:SUPG) today provided a regulatory updates for Dacogen(TM) (decitabine) injection for the treatment of myelodysplastic syndromes (MDS). ...
Cytokinetics, Incorporated Reports Third Quarter 2005 Financial ... Oct 26, 2005
Yahoo! News (press release) ...standard therapies and the other clinical trial is enrolling patients with acute leukemia, chronic myelogenous leukemia or advanced myelodysplastic syndromes. ...
MGI PHARMA Reports Third Quarter Financial Results Oct 19, 2005
Business Wire (press release), FDA shortly.". An Approvable Letter was received for Dacogen injection in myelodysplastic syndromes (MDS) on September 1, 2005. MGI ...
SuperGen Reports 2005 Third Quarter Financial Results Oct 20, 2005
PR Newswire (press release), ...letter from the US Food and Drug Administration or FDA which brings Dacogen that much closer to the patients suffering from Myelodysplastic Syndromes or MDS ...
New stem cell transplantation technique may match donor for every ... Oct 18, 2005
innovations report, The Bone Marrow Failure Scientific Symposium is presenting the latest advances in aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal ...
Street Chatter: Celgene, Toll Brothers, and Research in Motion ... Oct 19, 2005
Schaeffers Research, ...inflammatory diseases. Another drug candidate, REVLIMID, may treat multiple myeloma and myelodysplastic syndromes. Subsidiary Celgene ...
Vfend™ Reduces Infection of Central Nervous System in Cancer ... Oct 26, 2005
Cancer Consultants (press release), ...cancers are cancers that originate within blood cells; they include different forms of leukemias, lymphomas, multiple myeloma, or myelodysplastic syndromes. ...
MGI Pharma, Supergen fall on Dacogen delay Oct 26, 2005
MarketWatch MGI Pharma and Supergen have been seeking to have an injected form of Dacogen approved in the US and EU to treat myelodysplastic syndromes, a group of diseases ...
Pharmion Reports Third Quarter 2005 EPS of $0.27, Nine Month EPS ... Oct 25, 2005
PharmaLive.com (press release), Pharmion is currently sponsoring a study of 354 high-risk myelodysplastic syndromes (MDS) patients comparing Vidaza to best supportive care (BSC) with or ...
SuperGen, MGI Pharma say Europe may want more drug data Oct 26, 2005
East Bay Business Times, Dacogen is designed to treat myelodysplastic syndromes, a group of diseases in which bone marrow does not produce enough blood cells.
The Week Ahead: Sept. 12-16 10 Sep 2005
Administration will meet to discuss Revlimid, a new drug being developed by Celgene (nasdaq: CELG - news - people ) to treat myelodysplastic syndromes, a type ... Forbes
Oncologic Drugs Advisory Committee 10 Sep 2005
...proposed indication for the treatment of patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with ... FDA.gov
MGI, SuperGen Get Dacogen Approvable Letter, Have Hope Sep 2, 2005
The FDA issued an approvable letter for Dacogen (decitabine) injection, a treatment for myelodysplastic syndromes (MDS) that is partnered between MGI Pharma Inc ... BioWorld Online (subscription),
UPDATE 2-FDA asks for more info on MGI Pharma cancer drug Sep 1, 2005
...lower. The drug, called Dacogen, aims to treat myelodysplastic syndromes, a group of blood disorders that can lead to leukemia. ... Reuters
Health Stocks in Motion Sep 2, 2005
...received an approvable letter from the Food and Drug Administration for Dacogen injection, which is used for the treatment of myelodysplastic syndromes. ... TheStreet.com
Approvable Letter Received from the FDA for Dacogen(TM) ... Sep 1, 2005
...an approvable letter from the US Food and Drug Administration (FDA) for Dacogen(TM) (decitabine) injection for the treatment of myelodysplastic syndromes (MDS ... Genetic Engineering News,
SGX Latest To File For IPO Sep 2, 2005
...for use in combination with other leukemia medications, as a treatment for various solid tumors and as a treatment for myelodysplastic syndromes, better known ... SanDiego.com,
MGI Pharma "market outperform" Sep 2, 2005
...morning, the analysts mention that the company and SuperGen have received an approvable letter for Dacogen in the treatment of myelodysplastic syndromes (MDS). ... New Ratings
Highlights of rising and falling US stocks Sep 2, 2005
...lost 6.3% said they have received an approvable letter from the Food and Drug Administration for Dacogen injection, used to treat myelodysplastic syndromes. ... Investor's Business Daily (subscription)
Will Albertson's Go On Sale? Sep 2, 2005
...that they received an approvable letter from the Food and Drug Administration (FDA) for Dacogen injection, which is a treatment of myelodysplastic syndromes. ... BusinessWeek
MGI, SuperGen Hit After Hours Sep 1, 2005
...approval from the Food and Drug Administration for the Dacogen injection, a treatment for a group of bone marrow diseases called myelodysplastic syndromes. ... TheStreet.com
FDA needs more data to approve company's new drug Sep 1, 2005
...profile) received an approvable letter from the US Food and Drug Administration for Dacogen injection for the treatment of myelodysplastic syndromes (MDS), a ... MarketWatch
Stocks to Watch Sep 1, 2005
...profile) said they have received an approvable letter from the Food and Drug Administration for Dacogen injection, used to treat myelodysplastic syndromes. ... MarketWatch
Structural GenomiX Changes Corporate Name to SGX Pharmaceuticals Aug 31, 2005
In addition, SGX is developing Troxatyl for the treatment of Myelodysplastic Syndromes, or MDS, as well as for various solid tumors. ... PR Newswire (press release),
Structural GenomiX Initiates Phase 2/3 Trial of Troxatyl for the ... Aug 16, 2005
...recent work with this novel investigational agent have demonstrated considerable promise for treatment of both AML and myelodysplastic syndromes, for which ... PR Newswire (press release),
Sarasar®, a Farnesyl Transferase Inhibitor, Shows Activity in ... Aug 11, 2005
Farnesyl transferase inhibitors have been evaluated primarily in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). ... Cancer Consultants (press release),
Celgene "market outperform," target price raised Aug 17, 2005
The drug is likely to be approved in the near future for the treatment of multiple myeloma and myelodysplastic syndromes, the analysts add. ... New Ratings
'Blood sisters' Aug 12, 2005
Her "sissy" is Justess, 22 months old, who was diagnosed in May with a rare form of leukemia called Myelodysplastic syndromes (MDS), a disorder where the bone ... Pittsburgh Tribune-Review,
Pharmion expands into Corporate Woods, sees profits Aug 23, 2005
Its Vidaza drug, approved by the government last year, is used to treat Myelodysplastic Syndromes (MDS), a group of bone marrow disorders that can lead to ... Kansas City Star,
Bytes, August 22 Aug 21, 2005
...comand www.allaboutmds.comwere developed in conjunction with patients and physicians dealing with bone marrow failure disorders called myelodysplastic syndromes ... Rocky Mountain News,
US Panel Supports Celgene Drug Revlimid for Myelodysplastic ... -- Sep 15, 2005
A US advisory panel on Wednesday voted 10-5 to recommend approval of Celgene Corp.'s Revlimid to treat anemia in patients with myelodysplastic syndromes. ... / Cancerpage.com,
ODAC recommends Revlimid for low to intermediate-1-risk MDS ... -- Sep 15, 2005
Lenalidomide ) for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes ( MDS ) associated ... / Xagena.it,
Celgene's Revlimid Phase II Data Sufficient For Full Approval In ... -- Sep 14, 2005
FDA’s Oncologic Drugs Advisory Committee recommended full approval of Celgene’s Revlimid for myelodysplastic syndromes based on Phase II data. ... / FDA Advisory Committee
Business briefs, September 15 -- Sep 14, 2005
A panel of Food and Drug Administration advisers voted 10-5 to recommend that the agency clear Revlimid to treat myelodysplastic syndromes. ... / Rocky Mountain News,
New warning issued for colorectal drug -- Sep 14, 2005
...panel for cancer drugs recommended approval for a drug to treat anemia in people with certain kinds of blood disorders called myelodysplastic syndromes, or MDS ... / San Jose Mercury News,
Vical, Celgene help pace biotech gains -- Sep 15, 2005
...the agency approve its drug Revlimid for the treatment of transfusion-dependant anemia caused by blood cancers known at myelodysplastic syndromes, or MDS. ... / MarketWatch
US FDA staff raise issues with Celgene anemia drug -- Sep 12, 2005
Celgene is seeking FDA clearance to sell Revlimid to treat anemia in patients with blood disorders known as myelodysplastic syndromes. ... / Reuters
FDA and Celgene Revlimid(R) Briefing Documents for Advisory ... -- Sep 13, 2005
...for REVLIMID for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with ... / PR Newswire (press release),
Street Chatter: Celgene, Northwest Airlines, and Newmont Mining -- Sep 14, 2005
The medication treats a type of anemia that is associated with myelodysplastic syndromes, a group of diseases where the bone marrow doesn't produce enough ... / Schaeffers Research,
UPDATE 2-FDA asks for more info on MGI Pharma cancer drug -- Sep 1, 2005
...lower. The drug, called Dacogen, aims to treat myelodysplastic syndromes, a group of blood disorders that can lead to leukemia. ... / Reuters
The Week Ahead: Sept. 12-16 -- Sep 9, 2005
Administration will meet to discuss Revlimid, a new drug being developed by Celgene (nasdaq: CELG - news - people ) to treat myelodysplastic syndromes, a type ... / Forbes
Approvable Letter Received from the FDA for Dacogen(TM) ... -- Sep 1, 2005
...an approvable letter from the US Food and Drug Administration (FDA) for Dacogen(TM) (decitabine) injection for the treatment of myelodysplastic syndromes (MDS ... / Genetic Engineering News,
MGI, SuperGen Get Dacogen Approvable Letter, Have Hope -- Sep 2, 2005
The FDA issued an approvable letter for Dacogen (decitabine) injection, a treatment for myelodysplastic syndromes (MDS) that is partnered between MGI Pharma Inc ... / BioWorld Online (subscription),
MGI, SuperGen Hit After Hours -- Sep 1, 2005
...approval from the Food and Drug Administration for the Dacogen injection, a treatment for a group of bone marrow diseases called myelodysplastic syndromes. ... / TheStreet.com
FDA needs more data to approve company's new drug -- Sep 1, 2005
...profile) received an approvable letter from the US Food and Drug Administration for Dacogen injection for the treatment of myelodysplastic syndromes (MDS), a ... / MarketWatch
Will Albertson's Go On Sale? -- Sep 2, 2005
...that they received an approvable letter from the Food and Drug Administration (FDA) for Dacogen injection, which is a treatment of myelodysplastic syndromes. ... / BusinessWeek
Stocks to Watch -- Sep 1, 2005
...profile) said they have received an approvable letter from the Food and Drug Administration for Dacogen injection, used to treat myelodysplastic syndromes. ... / MarketWatch
Health Stocks in Motion -- Sep 2, 2005
...received an approvable letter from the Food and Drug Administration for Dacogen injection, which is used for the treatment of myelodysplastic syndromes. ... / TheStreet.com
SGX Latest To File For IPO -- Sep 2, 2005
...for use in combination with other leukemia medications, as a treatment for various solid tumors and as a treatment for myelodysplastic syndromes, better known ... / SanDiego.com,
MGI Pharma "market outperform" -- Sep 2, 2005
...morning, the analysts mention that the company and SuperGen have received an approvable letter for Dacogen in the treatment of myelodysplastic syndromes (MDS). ... / New Ratings
Arch Coal, Watson Pharma, and more -- Sep 2, 2005
...(SUPG) said they have received an approvable letter from the Food and Drug Administration for Dacogen injection, used to treat myelodysplastic syndromes. ... / Investor's Business Daily (subscription)
Structural GenomiX Changes Corporate Name to SGX Pharmaceuticals -- Aug 31, 2005
In addition, SGX is developing Troxatyl for the treatment of Myelodysplastic Syndromes, or MDS, as well as for various solid tumors. ... / PR Newswire (press release),
Structural GenomiX Initiates Phase 2/3 Trial of Troxatyl for the ... -- Aug 16, 2005
...recent work with this novel investigational agent have demonstrated considerable promise for treatment of both AML and myelodysplastic syndromes, for which ... / PR Newswire (press release),
Celgene "market outperform," target price raised -- Aug 17, 2005
The drug is likely to be approved in the near future for the treatment of multiple myeloma and myelodysplastic syndromes, the analysts add. ... / New Ratings
Pharmion expands into Corporate Woods, sees profits -- Aug 23, 2005
Its Vidaza drug, approved by the government last year, is used to treat Myelodysplastic Syndromes (MDS), a group of bone marrow disorders that can lead to ... / Kansas City Star,
| |
